Stirling Square clinches Medisup deal – report

The deal values the business at around €350m, equivalent to 14x EBITDA, the report added.

Stirling Square and Sagard were battling it out to acquire Medisup Sciences as of last week, Unquote sister publication Mergermarket reported at the time. Final bids were due on 22 March.

Information memorandums for the sale were distributed in early Q1, according to an earlier Mergermarket report, with Natixis handling the process.

Incorporated in 2006, Medisup offers courses for students preparing for admission tests for medicine, pharmacy and other medical science degree courses in France.

The business was marketed based on EBITDA of €20-25m, two sources told Mergermarket. According to the L'Agefi report, the business generates turnover of €60m. Groupe Chevrillon is currently invested in the business alongside management.

Stirling Square declined to comment when contacted by Unquote.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• France
• Consumer
• Stirling Square Capital Partners